Background There is no widely accepted framework to guide the development of condition-
specific preference-based instruments (CSPBIs) that includes both de novo and from …

Background: It is a familiar story. A promising multiple sclerosis (MS) treatment clears the
three regulatory hurdles of safety, quality and efficacy, only to fall at the fourth: cost …

Background Health-related quality of life (HRQoL) has not been assessed in Australians
with multiple sclerosis (MS) using a preferentially sensitive multi-attribute utility instrument …

Background Symptoms arising from vestibular system dysfunction are observed in 49–59%
of people with Multiple Sclerosis (MS). Symptoms may include vertigo, dizziness and/or …

Background A major debate in the quality-adjusted life-year (QALY) literature concerns
whose preferences should be used to estimate health state values (HSVs) and to calculate …

Background New interventions for multiple sclerosis (MS) commonly require a
demonstration of cost-effectiveness using health-related quality of life (HRQoL) utility values …

Cost-effectiveness analyses using quality-adjusted life-years (QALYs) are used in decision-
making regarding which interventions are available via many national healthcare systems …

Purpose Research indicates that employment is beneficial for people with multiple sclerosis
(MS). However, people with MS typically face reduced workforce participation compared to …

Breast cancer (BrC) is the most common cancer in women worldwide, however no BrC-
specific preference-based instrument exists. BrC and its treatments can impact patients' …

Background: In rare diseases such as multiple sclerosis (MS) the capture of data purely from
clinical trials or hospital cohorts is insufficient for fully understanding the multifaceted …